|
KMID : 1044520240870010012
|
|
Tuberculosis and Respiratory Diseases
2024 Volume.87 No. 1 p.12 ~ p.21
|
|
|
Tailored Biologics Selection in Severe Asthma
|
|
Kim Sang-Hyuk
Kim You-Lim
|
|
|
Abstract
|
|
|
The management of severe asthma presents a significant challenge in asthma treatment.
Over the past few decades, remarkable progress has been made in developingnew treatments for severe asthma, primarily in the form of biological agents. Theseadvances have been made possible through a deeper understanding of the underlyingpathogenesis of asthma. Most biological agents focus on targeting specific inflamma tory pathways known as type 2 inflammation. However, recent developments have introduceda new agent targeting upstream alarmin signaling pathways. This opens up newpossibilities, and it is anticipated that additional therapeutic agents targeting variouspathways will be developed in the future. Despite this recent progress, the mainstay ofasthma treatment has long been inhalers. As a result, the guidelines for the appropriateuse of biological agents are not yet firmly established. In this review, we aim to emphasizethe current state of biological therapy for severe asthma and provide insights intoits future prospects.
|
|
|
KEYWORD
|
|
|
Asthma, Lung Disease, Obstructive, Biological Products
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|